Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer

Triple-Negative Breast Carcinoma

(2014) Robert Schmadeka et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Breast cancer stem cells: Multiple capacities in tumor metastasis

(2014) Shao-Qing Geng et al.   CANCER LETTERS

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

(2014) M. D. Burstein et al.   CLINICAL CANCER RESEARCH

Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients

(2014) Carolin Bock et al.   Future Oncology

Clinicopathologic Characteristics of Breast Cancer Stem Cells Identified on the Basis of Aldehyde Dehydrogenase 1 Expression

(2014) Yoon Seok Kim et al.   Journal of Breast Cancer

Triple-negative breast cancer: future prospects in diagnosis and management

(2014) Shereef Elsamany et al.   MEDICAL ONCOLOGY

Patients with triple negative breast cancer: Is there an optimal adjuvant treatment?

(2013) Harold J. Burstein   BREAST

CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy

(2013) Rosa Nadal et al.   INTERNATIONAL JOURNAL OF CANCER

In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness

(2013) Federica Brugnoli et al.   Molecular Cancer

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

Epigenetic Regulation of Cancer Stem Cell Genes in Triple-Negative Breast Cancer

(2012) Naofumi Kagara et al.   AMERICAN JOURNAL OF PATHOLOGY

Breast cancer, side population cells and ABCG2 expression

(2012) K.M. Britton et al.   CANCER LETTERS

Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma

(2012) Banu Gun et al.   Diagnostic Pathology

CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer

(2012) T J Liu et al.   ONCOGENE

A CD44−/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer

(2011) Mohamed A. H. Ahmed et al.   BREAST CANCER RESEARCH AND TREATMENT

Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma

(2011) Po Zhao et al.   CANCER SCIENCE

ABCG2 is associated with HER-2 Expression, lymph node metastasis and clinical stage in breast invasive ductal carcinoma

(2011) Lei Xiang et al.   Diagnostic Pathology

Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer

(2011) Yasuyo Ohi et al.   HISTOPATHOLOGY

CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome

(2011) Michael O. Idowu et al.   HUMAN PATHOLOGY

Heterogeneity in breast cancer

(2011) Kornelia Polyak   JOURNAL OF CLINICAL INVESTIGATION

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Understanding the Dual Nature of CD44 in Breast Cancer Progression

(2011) J. M. V. Louderbough et al.   MOLECULAR CANCER RESEARCH

Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status

(2010) Hee Jeong Kim et al.   BREAST

The CD44+/CD24− phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients

(2010) Alexandra Giatromanolaki et al.   MEDICAL ONCOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature

(2009) Emmanuelle Charafe-Jauffret et al.   CANCER RESEARCH

CD133 as a Marker for Cancer Stem Cells: Progresses and Concerns

(2009) Yaojiong Wu et al.   STEM CELLS AND DEVELOPMENT